Ken Song

As T-cell engagers (TCEs) rapidly emerge from oncology into the autoimmune space, the field is facing a crucial inflection point: how do TCEs stack up against T-cell therapies in terms of specificity, efficacy, and durability? This panel brings together leading voices spanning TCE and cell therapy modalities to debate how these technologies co-exist, compete, or converge. The conversation will also explore how companies are strategically selecting antigens and indications, and designing pipelines that balance scientific ambition with clinical practicality.

Our expert panelists will:

• Compare the pros and cons of TCEs and engineered cell therapies in autoimmune diseases and their mechanistic strengths
• Discuss how to target the right antigens with the right modality: designing pipelines that align antigen biology with the optimal therapeutic platform
• Debate how durability of response and immune reprogramming differ between modalities, and whether one can truly replace the other
• Strategize how to build a future-proof autoimmune pipeline with complementary or competitive assets across modalities

• Introducing cizutamig and CND261, a BCMAxCD3 and CD20xCD3 bispecific T-Cell engager, respectively. Both were originally developed in oncology and are now advancing into autoimmune disease
• Discussing what is known and unknown on targeting different B cell antigens (e.g. BCMA, CD19, CD20) to maximize clinical benefit in autoimmune diseases
• Sharing views on different product profiles with TCEs beyond just immune reset